Roche Holding Company Profile (VTX:ROG)

About Roche Holding (VTX:ROG)

Roche Holding logoRoche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: VTX:ROG
  • CUSIP: N/A
  • Web: N/A
Average Prices:
  • 50 Day Moving Avg: CHF 97.02
  • 200 Day Moving Avg: CHF 83.62
P/E:
  • Trailing P/E Ratio: 32.24
  • P/E Growth: 1.35
Dividend:
  • Dividend Yield: 1.0%
 

Frequently Asked Questions for Roche Holding (VTX:ROG)

What is Roche Holding's stock symbol?

Roche Holding trades on the VTX under the ticker symbol "ROG."

Where is Roche Holding's stock going? Where will Roche Holding's stock price be in 2017?

6 brokerages have issued 1-year price objectives for Roche Holding's shares. Their forecasts range from CHF 290 to CHF 335. On average, they expect Roche Holding's share price to reach CHF 312.50 in the next year. View Analyst Ratings for Roche Holding.

Who are some of Roche Holding's key competitors?

Analyst Ratings

Consensus Ratings for Roche Holding (VTX:ROG) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: CHF 312.50

Analysts' Ratings History for Roche Holding (VTX:ROG)
Show:
DateFirmActionRatingPrice TargetDetails
5/26/2017Goldman Sachs Group IncSet Price TargetBuyCHF 335View Rating Details
5/20/2017Morgan StanleySet Price TargetBuyCHF 290View Rating Details
5/20/2017Jefferies Group LLCSet Price TargetBuyCHF 305View Rating Details
5/20/2017JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details
5/20/2017Barclays PLCSet Price TargetBuyCHF 320View Rating Details
11/3/2016Citigroup IncReiterated RatingBuyView Rating Details
(Data available from 5/26/2015 forward)

Earnings

Earnings History for Roche Holding (VTX:ROG)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Roche Holding (VTX:ROG)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Roche Holding (VTX:ROG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Roche Holding (VTX:ROG)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Roche Holding (VTX:ROG)
Latest Headlines for Roche Holding (VTX:ROG)
Source:
DateHeadline
nasdaq.com logoDeadly brain infection in German MS patient prompts Roche investigation - Nasdaq
www.nasdaq.com - May 24 at 8:01 PM
finance.yahoo.com logoRogers to Participate in B. Riley & Co. Annual Investor Conference
finance.yahoo.com - May 24 at 9:42 AM
americanbankingnews.com logoRoche Holding Ltd. (ROG) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - May 22 at 8:38 AM
americanbankingnews.com logoRoche Holding Ltd. (ROG) PT Set at CHF 320 by Barclays PLC
www.americanbankingnews.com - May 21 at 11:46 PM
americanbankingnews.com logoRoche Holding Ltd. (ROG) Given a CHF 335 Price Target at Goldman Sachs Group Inc
www.americanbankingnews.com - May 21 at 11:46 PM
americanbankingnews.com logoRoche Holding's (ROG) "Buy" Rating Reaffirmed at JPMorgan Chase & Co.
www.americanbankingnews.com - May 21 at 11:08 PM
americanbankingnews.com logoRoche Holding Ltd. (ROG) Given a CHF 305 Price Target at Jefferies Group LLC
www.americanbankingnews.com - May 21 at 3:04 PM
americanbankingnews.com logoRoche Holding Ltd. (ROG) Given a CHF 290 Price Target by Morgan Stanley Analysts
www.americanbankingnews.com - May 21 at 11:20 AM
nasdaq.com logoImmunoGen drug moving ahead in single-agent, combination trials - Nasdaq
www.nasdaq.com - May 17 at 7:30 PM
nasdaq.com logoMerck says test shows Keytruda improves survival for bladder cancer patients - Nasdaq
www.nasdaq.com - May 17 at 7:30 PM
finance.yahoo.com logoRogers to Participate in Houlihan Lokey Global Industrial Conference
finance.yahoo.com - May 17 at 7:30 PM
nasdaq.com logoRegeneron profit misses estimates as Eylea sales growth slows - Nasdaq
www.nasdaq.com - May 5 at 8:09 AM
finance.yahoo.com logoETFs with exposure to Rogers Corp. : May 4, 2017
finance.yahoo.com - May 4 at 7:50 PM
finance.yahoo.com logoRogers Corp. :ROG-US: Earnings Analysis: Q1, 2017 By the Numbers : May 3, 2017
finance.yahoo.com - May 3 at 7:23 PM
nasdaq.com logoU.S. FDA approves AstraZeneca's immunotherapy for bladder cancer - Nasdaq
www.nasdaq.com - May 2 at 9:45 AM
marketwatch.com logoRoche revenue rises 4% on strong sales - MarketWatch
www.marketwatch.com - April 27 at 8:01 PM
finance.yahoo.com logoWhy Rogers Corp. Soared Today
finance.yahoo.com - April 27 at 8:01 PM
nasdaq.com logoEMA panel recommends nod for Sanofi, Regeneron's arthritis drug - Nasdaq
www.nasdaq.com - April 23 at 9:08 AM
finance.yahoo.com logoRogers Corp. – Value Analysis (NYSE:ROG) : April 21, 2017
finance.yahoo.com - April 21 at 7:22 PM
finance.yahoo.com logoRogers Corp. breached its 50 day moving average in a Bullish Manner : ROG-US : April 20, 2017
finance.yahoo.com - April 20 at 8:30 AM
finance.yahoo.com logoRogers Schedules First Quarter 2017 Earnings Call for April 27
finance.yahoo.com - April 19 at 7:32 PM
americanbankingnews.com logoRoche Holding Ltd. (ROG) Earns Buy Rating from JPMorgan Chase & Co.
www.americanbankingnews.com - April 18 at 10:37 AM
nasdaq.com logoBristol-Myers to license two drugs to Biogen, Roche - Nasdaq
www.nasdaq.com - April 15 at 8:27 AM
americanbankingnews.com logoJPMorgan Chase & Co. Reaffirms "Buy" Rating for Roche Holding Ltd. (ROG)
www.americanbankingnews.com - April 8 at 5:32 PM
finance.yahoo.com logoTrump's big pharma impact
finance.yahoo.com - April 7 at 12:20 PM
finance.yahoo.com logoRogers Corp. breached its 50 day moving average in a Bearish Manner : ROG-US : April 6, 2017
finance.yahoo.com - April 7 at 12:20 PM
americanbankingnews.com logoRoche Holding's (ROG) "Buy" Rating Reaffirmed at Goldman Sachs Group Inc
www.americanbankingnews.com - March 31 at 7:17 AM
americanbankingnews.com logoRoche Holding Ltd. (ROG) Rating Reiterated by JPMorgan Chase & Co.
www.americanbankingnews.com - March 30 at 3:45 PM
americanbankingnews.com logoRoche Holding's (ROG) "Buy" Rating Reiterated at Goldman Sachs Group Inc
www.americanbankingnews.com - March 30 at 7:16 AM
americanbankingnews.com logoRoche Holding Ltd. (ROG) Stock Rating Reaffirmed by Goldman Sachs Group Inc
www.americanbankingnews.com - March 27 at 11:38 AM
nasdaq.com logoFDA approves Pfizer, German Merck immunotherapy for skin cancer - Nasdaq
www.nasdaq.com - March 25 at 7:12 PM
thestreet.com logoMylan Settles With Genentech Over Patents for Breast Cancer Drug - TheStreet.com
www.thestreet.com - March 15 at 8:59 AM
nasdaq.com logoBUZZ-US STOCKS ON THE MOVE-Abercrombie, Kroger, PTC, Rada, Broadcom - Nasdaq
www.nasdaq.com - March 2 at 7:44 PM
nasdaq.com logoUPDATE 2-Roche trial finds new drug cocktail cuts breast cancer deaths - Nasdaq
www.nasdaq.com - March 2 at 8:12 AM
nasdaq.com logoNovartis cancer drug Zykadia gets FDA priority review - Nasdaq
www.nasdaq.com - February 23 at 8:20 AM
finance.yahoo.com logoEdited Transcript of ROG earnings conference call or presentation 21-Feb-17 2:00pm GMT
finance.yahoo.com - February 22 at 9:39 AM
finance.yahoo.com logoRogers (ROG) Shows Strength: Stock Adds 9.8% in Session
finance.yahoo.com - February 22 at 9:39 AM
finance.yahoo.com logoRogers Corporation Reports Fourth Quarter 2016 and Full Year Results
finance.yahoo.com - February 20 at 6:47 PM
finance.yahoo.com logoRogers Schedules Q4 & Full Year 2016 Earnings Call for Feb 21
finance.yahoo.com - February 10 at 11:05 PM
nasdaq.com logoRoche said to consider options for Diabetes unit- Bloomberg - Nasdaq
www.nasdaq.com - February 1 at 3:44 AM
reuters.com logoBristol-Myers cuts 2017 outlook amid Opdivo competition - Reuters
www.reuters.com - January 27 at 2:24 AM
nasdaq.com logoEurope's oncologists back biosimilar versions of cancer drugs ... - Nasdaq
www.nasdaq.com - January 18 at 8:13 PM
finance.yahoo.com logoTweedy Browne Global Value Buys , , , Sells Hasbro Inc, , - Yahoo Finance
finance.yahoo.com - January 10 at 10:10 PM
finance.yahoo.com logoBallard Power (BLDP) Looks Good: Stock Moves 9.5% Higher
finance.yahoo.com - December 20 at 2:20 PM
finance.yahoo.com logoBlueprint Medicines Announces Appointment of Marion Dorsch, Ph.D. as Chief Scientific Officer and the …
finance.yahoo.com - November 14 at 7:32 PM
seekingalpha.com logoRoche's Actemra successful in late-stage study in giant cell arteritis
seekingalpha.com - November 14 at 7:32 PM
reuters.com logoRegeneron profit tops Street on lower costs - Reuters
www.reuters.com - November 4 at 6:46 PM
biz.yahoo.com logoROGERS CORP Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - November 3 at 11:29 AM
finance.yahoo.com logo4:58 pm Rogers Corp beats by $0.13, beats on revs; guides Q4 EPS in-line
finance.yahoo.com - November 2 at 7:32 PM
biz.yahoo.com logoQ3 2016 Rogers Corp Earnings Release - After Market Close
biz.yahoo.com - November 2 at 10:44 AM

Social

Social activity is not available for this stock.
This page was last updated on 5/26/2017 by MarketBeat.com Staff